B

Blueprint Medicines Tech Stack

Biopharmaceutical company focused on allergy/inflammation and oncology medicines

Biotechnology Research Cambridge, Massachusetts 501–1,000 employees Founded 2011 Public Company

Blueprint Medicines is a public biopharmaceutical company operating two approved medicines across allergy/inflammation and oncology/hematology. The hiring profile is heavily weighted toward marketing and sales leadership (14 of 19 active roles), with concurrent focus on market development and patient access—suggesting a shift from research-stage to commercialization and geographic expansion. Data integration challenges and Veeva friction appear in their pain-point list, indicating scaling pressures as they move products from approval to market.

Tech Stack 11 technologies

Core StackTableau Python Veeva IQVIA Komodo Microsoft Office Excel PowerPoint Tableau Cloud SQL R

What Blueprint Medicines Is Building

◆Challenges

Building new market
Removing operational barriers
New market development
Patient access challenges
Shifting to customer-centric model
Underdiagnosis of systemic mastocytosis
Product demand
Patient outcomes
Data flow integration issues
Veeva integration challenges

▲Active Projects

Ayvakit launch
New market development
National care projects
National working groups
Business partnership development
Advisory board programs
Congress engagement initiatives
Ayvakyt launch marketing
German congress oversight
National omnichannel strategy

Hiring Activity

Accelerating20 roles · 10 in 30d

Department

Marketing

8

Sales

6

Ops

2

Data

1

Healthcare

1

Seniority

Senior

9

Director

6

Manager

2

Mid

1

Notable leadership hires: Marketing Lead, Medical Lead

Company intelligence

Find more companies like Blueprint Medicines by tech stack, pain points and active projects

Get started free

About Blueprint Medicines

Blueprint Medicines is a Cambridge-based, publicly traded biopharmaceutical company founded in 2011 and now a subsidiary of Sanofi. The company develops targeted therapies in two therapeutic areas: allergy/inflammation (including systemic mastocytosis and chronic urticaria) and oncology/hematology (including breast cancer and solid tumors). Two approved medicines are in market across the U.S. and Europe. The commercial engine is ramping: active hiring across marketing, sales, operations, and healthcare roles spans the U.S., Germany, France, and the U.K., with a leadership emphasis on medical and marketing functions. The technology foundation includes Veeva, Tableau, IQVIA, and custom analytics (Python, R, SQL).

HeadquartersCambridge, Massachusetts

Company Size501–1,000 employees

Founded2011

Hiring MarketsGermany, United Kingdom, France, United States

Frequently Asked Questions

What is Blueprint Medicines' pipeline?

The company is advancing programs in systemic mastocytosis, chronic urticaria, breast cancer, and other solid tumors, ranging from early science through advanced clinical trials. Two medicines are already approved in the U.S. and Europe.

What tech stack does Blueprint Medicines use?

Veeva, Tableau, IQVIA, Komodo, SQL, R, Python, Microsoft Office, and Tableau Cloud. The company is managing data flow integration and Veeva integration as operational priorities.